Symbol | Exchange | Currency |
|---|
Avadel Pharmaceuticals plc (Nasdaq: NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that LUMRYZ is now commercially...
-LUMRYZ is the first and only once-at-bedtime oxybate for people living with narcolepsy -Once-nightly dosing regimen of LUMRYZ has been found by FDA to provide a major...
Investing.com - Avadel Pharma (NASDAQ: AVDL) reported first quarter EPS of $-0.480, $0.13 worse than the analyst estimate of $-0.350. Revenue for the quarter came in at $0.00...
DUBLIN, Ireland, June 01, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives,...
– 12 accepted abstracts highlight Company’s emerging leadership in narcolepsy – – Data adds to growing body of evidence demonstrating positive clinical benefit and patient...
A lot happened in the markets this past week. And perhaps the best analogy to explain it all rests with one obscure development in the broader world of economics: The price of eggs...
Avadel Pharmaceuticals plc is a biopharmaceutical company. The Company's lead product candidate, FT218, is an investigational once-nightly, extended-release formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy. Its drug delivery technologies include Micropump, LiquiTime, and Medusa. Its Micropump drug-delivery technology allows for the controlled delivery of small molecule drugs taken orally, which improves dosing compliance, reduces toxicity and improves patient compliance. Its LiquiTime technology allows for development of modified release oral products in a liquid suspension formulation, which makes such formulations particularly well suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of modified-release-injectable dosage formulations of drugs, such as peptides, polypeptides, proteins, and small molecules.
| Average | 16.950 (+15.858% Upside) |
| High | 26.000 |
| Low | 7.000 |
| Price | 14.630 |
| No. of Analysts | 10 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Sell | Buy | Strong Buy | Strong Buy |
| Technical Indicators | Strong Sell | Sell | Strong Buy | Strong Buy | Strong Buy |
| Summary | Strong Sell | Sell | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 501.00 | 501.00 | 501.00 | 0.00 | 0.00% | 0.00 | London | |||
| 147.50 | 147.50 | 147.50 | +2.50 | +1.72% | 104.49K | London | |||
| 44.50 | 44.50 | 44.15 | +0.15 | +0.34% | 540.67K | London | |||
| 535.00 | 546.00 | 512.00 | 0.00 | 0.00% | 0.00 | London | |||
| 24.75 | 25.00 | 25.00 | -1.000 | -3.88% | 50.34K | London | |||
| 2.50 | 2.50 | 2.50 | 0.00 | 0.00% | 0.00 | London | |||
| 256.00 | 259.00 | 255.00 | -2.00 | -0.78% | 43.69K | London | |||
| 383.50 | 385.00 | 382.00 | +0.50 | +0.13% | 151.13K | London | |||
Invista REIM Holdingsderived | 14.625 | 9.00 | 14.625 | 0.00 | 0.00% | 0.00 | London | ||
| 25.00 | 25.00 | 25.00 | 0.00 | 0.00% | 0.00 | London | |||
| 253.00 | 255.00 | 253.00 | -6.00 | -2.32% | 51.29K | London | |||
| 57.70 | 58.10 | 57.40 | -0.10 | -0.17% | 1.79M | London | |||
| 0.02 | 0.02 | 0.016 | 0.00 | 0.00% | 0.00 | London | |||
| 406.50 | 411.00 | 400.00 | +2.50 | +0.62% | 88.20K | London | |||
Aegis Groupderived | 239.80 | 240.00 | 239.70 | 0.00 | 0.00% | 0.00 | London |